Abbott will expand its existing agreement with GlaxoSmithKline Biologicals (GSK) to include the development of an additional companion diagnostic test in support of GSK’s cancer immunotherapy research program.
Companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more or less likely to benefit from a particular therapy.
The existing agreements between the two companies, announced in July 2009 and March 2010 , focused on the development of PCR (polymerase chain reaction) tests to screen non-small cell lung cancer and melanoma tumors for expression of the MAGE-A3 antigen.
Under the expanded agreement, Abbott will develop a PCR test for use on the Abbott m2000rt instrument to screen non-small cell lung cancer tumors for the expression of the PRAME antigen.
PRAME is a preferentially expressed antigen of melanoma that is expressed in 69 percent of non-small cell lung cancer cases, as well as in a wide variety of cancer types, including melanoma, breast, ovarian, and bladder cancer, with limited expression in normal cells.
Purchase the on-demand report Partnering Agreements with GlaxoSmithKline
See the full deal data at Current Agreements (subscription required)